NETRIS Pharma has a first candidate in clinical Phase I, which targets the Netrin-1 ligand

Four other programs are in preclinical research or development stages

NETRIS Pharma is developing a pipeline of drug candidates that target different Dependence Receptors/ligands.

These candidates are at various stages of development: from lead identification, animal proof of concept to clinical Phase I.

NETRIS Pharma focuses its development activities on monoclonal antibodies.

NETRIS Pharma puts intellectual property at the center of its strategy.

The company holds worldwide exclusive rights and patents on major aspects of its activity and development.

Contact Us